Philips

PHG

Market cap $28.6B

Philips N.V. (PHG) is rated a conservative 'Buy' with a maintained price target, reflecting 20%+ annualized upside potential. PHG's leadership in imaging, healthcare AI, and a strong moat in diagnosis and treatment underpin the investment case despite historical missteps. Litigation resolution, productivity initiatives, and a 40–50% dividend payout target support margin expansion and forward earnings growth.

December 15, 2025 Acquisition of SpectraWAVE's next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE's technologies have the potential to significantly increase adoption of coronary intravascular imaging and physiological assessment, especially when combined with Philips' industry-leading Azurion image-guided therapy platform, supporting better outcomes [2] for more cardiac patients Acquisition will expand Philips' existing intravascular imaging and physiological assessment device portfolio, featuring Eagle Eye Platinum digital IVUS and OmniWire iFR technology, to create a comprehensive offering in intravascular imaging and physiology solutions Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging [3]. SpectraWAVE's intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide [4].

Koninklijke Philips NV (NYSE: PHG) shares fell sharply on Thursday, marking their most significant single-day drop since February.

December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company's previously communicated schedule. As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow.

Polarean's FDA cleared coil achieves important milestone, expanding clinical reach Polarean's FDA cleared coil achieves important milestone, expanding clinical reach

December 1, 2025 Commercial availability expanded across Europe and the United States Real-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular procedures LumiGuide seamlessly integrates with Azurion, Philips' proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA, a global leader in health technology, today announced the expanded commercial availability of LumiGuide 3D Device Guidance, the world's first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States. LumiGuide represents a breakthrough in radiation-free* navigation, allowing physicians to visualize and guide devices inside the body using light instead of continuous X-ray.

Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) stock popped 12% to 0.14p on Monday after the company cleared a major technical hurdle in its bid to get Xenon-based lung scans into more hospitals. Philips has signed off on Polarean's XENOVIEW 3T chest coil, confirming it plays nicely with the Dutch giant's next wave of 3-tesla MRI scanners.

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has cleared a key hurdle in its push to expand the reach of its Xenon-based lung scans, after its dedicated chest coil passed compatibility testing with Philips' latest magnetic resonance imaging systems. The company said Philips had completed its own validation of the XENOVIEW 3T Chest Coil, which was cleared by the US Food and Drug Administration last year.

November 30, 2025 Philips pioneered detector-based spectral CT, which has been widely adopted in clinical routine exams across anatomies, supported by over 800 peer-reviewed publications [1] CE-marked, 510k pending Verida CT [2] integrates AI across the imaging chain, providing superb image quality while accelerating workflow and reducing dose [3, 4] Amsterdam, the Netherlands and Chicago, USA – At RSNA 2025, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Verida, the world's first detector-based spectral CT fully powered by AI. This marks a transformative milestone in CT, with AI optimizing the entire imaging chain – lowering system noise, elevating image quality, and accelerating clinical workflow.

November 30, 2025 Major technology breakthrough combines advanced AI for clinical insights and accelerated workflow in new premium 3.0T MRI platform [1] Amsterdam, the Netherlands, and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled BlueSeal Horizon [1], an entirely new 3.0T MRI innovation platform that includes the industry's first helium-free 3.0T magnet at RSNA 2025. A pivotal advance in MRI innovation, helium-free [2] 3.0T is a major scientific achievement set to have significant impact for health providers and patients.